Genoway: peers
Genoway beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Genoway, GenSight Biologics S.A., Abionyx Pharma SA, Poxel S.A., Genkyotex SA, Fermentalg Societe Anonyme, Onxeo SA, OSE Immunotherapeutics SA: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Genowaybase JEH.F · 🇫🇷 FR Percentile in Healthcare Percentile in France | GenSight Biologics S.A. SIGHT.PA · 🇫🇷 FR Percentile in Healthcare Percentile in France | Abionyx Pharma SA ABNX.PA · 🇫🇷 FR Percentile in Healthcare Percentile in France | Poxel S.A. POXEL.PA · 🇫🇷 FR Percentile in Healthcare Percentile in France | Genkyotex SA G061.F · 🇫🇷 FR Percentile in Healthcare Percentile in France | Fermentalg Societe Anonyme 1F6.F · 🇫🇷 FR Percentile in Healthcare Percentile in France | Onxeo SA ONXEO.CO · 🇫🇷 FR Percentile in Healthcare Percentile in France | OSE Immunotherapeutics SA OSE.PA · 🇫🇷 FR Percentile in Healthcare Percentile in France | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $36 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8 | $34 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $45 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $22 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8 | $41 Mlast known, Jan 1, 2021 · Market dataLast known value: no current one4th of 8 | $30 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one7th of 8 | $46 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one2nd of 8 | $101 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one1st of 8 | $39 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $2 MFY2024 · ESEF4th of 4 | $5 MFY2025 · ESEF2nd of 4 | $7 MFY2024 · ESEF1st of 4 | —— | —— | —— | $3 MFY2025 · ESEF3rd of 4 | $4 M4 ranked |
| Net income (Higher is better) | —— | $-15 MFY2024 · ESEF2nd of 4 | $-6 MFY2025 · ESEF1st of 4 | $-20 MFY2024 · ESEF3rd of 4 | —— | —— | —— | $-42 MFY2025 · ESEF4th of 4 | $-17 M4 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +18.3%FY2024 · ESEF2nd of 365th93rd | -7.1%FY2025 · ESEF3rd of 315th11th | +235.5%FY2024 · ESEF1st of 397th98th | ———— | ———— | ———— | ———— | +18.3%3 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | 55.7%FY2024 · ESEFonly one with it45th52nd | ———— | ———— | ———— | ———— | 55.7%— |
| Operating margin (Higher is better) | ———— | ———— | -136.2%FY2025 · ESEF2nd of 220th4th | -52.8%FY2024 · ESEF1st of 231st8th | ———— | ———— | ———— | ———— | -94.5%2 ranked |
| Net margin (Higher is better) | ———— | -935.2%FY2024 · ESEF3rd of 30th0th | -136.7%FY2025 · ESEF1st of 319th4th | -275.9%FY2024 · ESEF2nd of 312th2nd | ———— | ———— | ———— | ———— | -275.9%3 ranked |
| Free cash flow margin (Higher is better) | ———— | -864.2%FY2024 · ESEF2nd of 21st1st | -78.2%FY2025 · ESEF1st of 224th12th | ———— | ———— | ———— | ———— | ———— | -471.2%2 ranked |
| Return on equity (Higher is better) | ———— | ———— | -95.5%FY2025 · ESEF2nd of 226th3rd | ———— | ———— | ———— | ———— | -85.9%FY2025 · ESEF1st of 229th4th | -90.7%2 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 1 of 3FY2024 · Scorecard2nd of 4 | 0 of 6FY2025 · Scorecard3rd of 4 | 2 of 4FY2024 · Scorecard1st of 4 | —— | —— | —— | 0 of 3FY2025 · Scorecard3rd of 4 | 17% passed4 ranked |
| Growth checks (Higher is better) | —— | 1 of 2FY2024 · Scorecard1st of 4 | 0 of 2FY2025 · Scorecard3rd of 4 | 1 of 2FY2024 · Scorecard1st of 4 | —— | —— | —— | 0 of 1FY2025 · Scorecard3rd of 4 | 25% passed4 ranked |
| Profitability checks (Higher is better) | —— | 0 of 1FY2024 · Scorecard2nd of 4 | 0 of 4FY2025 · Scorecard2nd of 4 | 1 of 2FY2024 · Scorecard1st of 4 | —— | —— | —— | 0 of 2FY2025 · Scorecard2nd of 4 | 0% passed4 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Genoway: How market caps are worked out; GenSight Biologics S.A.: How market caps are worked out; Abionyx Pharma SA: How market caps are worked out; Poxel S.A.: How market caps are worked out; Genkyotex SA: How market caps are worked out; Fermentalg Societe Anonyme: How market caps are worked out; Onxeo SA: How market caps are worked out; OSE Immunotherapeutics SA: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Genoway | — | — | — |
| GenSight Biologics S.A. | — | — | — |
| Abionyx Pharma SA | -136.2%FY2025 | 20th percentile in Healthcaremedian -7.7%, 674 companies | 4th percentile in Francemedian 5.5%, 124 companies |
| Poxel S.A. | -52.8%FY2024 | 31st percentile in Healthcaremedian -7.7%, 674 companies | 8th percentile in Francemedian 5.5%, 124 companies |
| Genkyotex SA | — | — | — |
| Fermentalg Societe Anonyme | — | — | — |
| Onxeo SA | — | — | — |
| OSE Immunotherapeutics SA | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Genoway | GenSight Biologics S.A. | Abionyx Pharma SA | Poxel S.A. | Genkyotex SA | Fermentalg Societe Anonyme | Onxeo SA | OSE Immunotherapeutics SA |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | $5 MESEF1st | — | — | — | — | $3 MESEF2nd |
| 2024 | — | $2 MESEF4th | $5 MESEF3rd | $7 MESEF2nd | — | — | — | $76 MESEF1st |
| 2023 | — | $1 MESEF2nd | — | $2 MESEF1st | — | — | — | — |
| 2022 | — | — | $6 MESEF | — | — | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Genoway#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- GenSight Biologics S.A.SIGHT.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $34 M market cap against $36 M · Same country: France · Ratios of the last two fiscal years on fileMarket cap $34 M (last known, Jan 5, 2024) · revenue $2 M (year to December 2024)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Abionyx Pharma SAABNX.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $45 M market cap against $36 M · Same country: France · Ratios of the last two fiscal years on fileMarket cap $45 M (last known, Jan 5, 2024) · revenue $5 M (year to December 2025)98 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Poxel S.A.POXEL.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $22 M market cap against $36 M · Same country: France · Ratios of the last two fiscal years on fileMarket cap $22 M (last known, Jan 5, 2024) · revenue $7 M (year to December 2024)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Genkyotex SAG061.F · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $41 M market cap against $36 M · Same country: FranceMarket cap $41 M (last known, Jan 1, 2021)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Fermentalg Societe Anonyme1F6.F · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $30 M market cap against $36 M · Same country: FranceMarket cap $30 M (last known, Jul 30, 2023)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Onxeo SAONXEO.CO · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $46 M market cap against $36 M · Same country: FranceMarket cap $46 M (last known, Jan 7, 2022)93 of 100 (industry or sector 50 + size 28 + country 15)In the group
- OSE Immunotherapeutics SAOSE.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $101 M market cap against $36 M · Same country: France · Ratios of the last two fiscal years on fileMarket cap $101 M (last known, Jan 5, 2024) · revenue $3 M (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)In the group
- Nicox SACOX.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $61 M market cap against $36 M · Same country: FranceMarket cap $61 M (last known, Dec 25, 2022) · revenue $9 M (year to December 2021)92 of 100 (industry or sector 50 + size 27 + country 15)+ Add
- NFL Biosciences SAALNFL.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $19 M market cap against $36 M · Same country: FranceMarket cap $19 M (last known, Jan 5, 2024)91 of 100 (industry or sector 50 + size 26 + country 15)+ Add
- Transgene SATNG.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $151 M market cap against $36 M · Same country: France · Ratios of the last two fiscal years on fileMarket cap $151 M (last known, Jan 5, 2024) · revenue $0 M (year to December 2025)91 of 100 (industry or sector 50 + size 21 + country 15 + figures on file 5)+ Add
- Oncodesign Societe AnonymeALONC.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $80 M market cap against $36 M · Same country: FranceMarket cap $80 M (last known, Jan 7, 2022)90 of 100 (industry or sector 50 + size 25 + country 15)+ Add
- Adocia SAADOC.PA · 🇫🇷 FranceSame industry: Biotechnology · Similar size: $177 M market cap against $36 M · Same country: France · Ratios of the last two fiscal years on fileMarket cap $177 M (last known, Jan 5, 2024) · revenue $2 M (year to December 2025)90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.